Search research articles
Contact Us
Filters
Showing results (131-140 of 234) with videos related to
Page
of 24
Sort By:
Radiology
|
March 31, 2026
PSMA PET/CT-derived Tumor Volume for Predicting Outcomes in Patients with Metastatic Castration-Resistant Prostate Cancer Receiving <sup>177</sup>Lu-PSMA-617
Alireza Ghodsi, Lukas Owens, Ridvan Arda Demirci, et al.
British Journal of Clinical Pharmacology
|
January 14, 2022
Exposure-response relationship of ramucirumab in RANGE, a randomized phase III trial in advanced urothelial carcinoma refractory to platinum therapy
Ronald de Wit, Thomas Powles, Daniel Castellano, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
October 1, 2014
Quantitative and stoichiometric analysis of the microRNA content of exosomes
John R Chevillet, Qing Kang, Ingrid K Ruf, et al.
American Journal of Nuclear Medicine and Molecular Imaging
|
January 22, 2026
Results from a prospective registry of <sup>18</sup>F-Fluciclovine PET/CT use in prostate cancer management: a cautionary lesson for implementation of PSMA PET
Steven Blinka, Risa L Wong, Sarah K Holt, et al.
Advances in Radiation Oncology
|
April 7, 2022
A Prospective Study of a Resorbable Intravesical Fiducial Marker for Bladder Cancer Radiation Therapy
Matthew D Greer, Stephanie K Schaub, Stephen R Bowen, et al.
The Lancet. Oncology
|
February 8, 2022
Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial
Matthew R Smith, Howard I Scher, Shahneen Sandhu, et al.
European Urology
|
July 16, 2019
Incremental Utility of Adjuvant Chemotherapy in Muscle-invasive Bladder Cancer: Quantifying the Relapse Risk Associated with Therapeutic Effect
Filippo Pederzoli, Marco Bandini, Alberto Briganti, et al.
Clinical Genitourinary Cancer
|
September 20, 2017
Venous Thromboembolism Risk in Patients With Locoregional Urothelial Tract Tumors
Jorge D Ramos, Jonathan T Wingate, Roman Gulati, et al.
Bladder Cancer (Amsterdam, Netherlands)
|
June 10, 2021
Plasmacytoid urothelial carcinoma: response to chemotherapy and oncologic outcomes
Leonidas N Diamantopoulos, Ali Raza Khaki, Petros Grivas, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 14, 2021
Phase II Multicenter Study of Enzalutamide in Metastatic Castration-Resistant Prostate Cancer to Identify Mechanisms Driving Resistance
Rana R McKay, Lucia Kwak, Jett P Crowdis, et al.
Page
of 24
Search research articles
Search
Showing results (131-140 of 234) with videos related to
Sort By:
Page
of 24
Radiology
|
March 31, 2026
PSMA PET/CT-derived Tumor Volume for Predicting Outcomes in Patients with Metastatic Castration-Resistant Prostate Cancer Receiving <sup>177</sup>Lu-PSMA-617
Alireza Ghodsi, Lukas Owens, Ridvan Arda Demirci, et al.
British Journal of Clinical Pharmacology
|
January 14, 2022
Exposure-response relationship of ramucirumab in RANGE, a randomized phase III trial in advanced urothelial carcinoma refractory to platinum therapy
Ronald de Wit, Thomas Powles, Daniel Castellano, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
October 1, 2014
Quantitative and stoichiometric analysis of the microRNA content of exosomes
John R Chevillet, Qing Kang, Ingrid K Ruf, et al.
American Journal of Nuclear Medicine and Molecular Imaging
|
January 22, 2026
Results from a prospective registry of <sup>18</sup>F-Fluciclovine PET/CT use in prostate cancer management: a cautionary lesson for implementation of PSMA PET
Steven Blinka, Risa L Wong, Sarah K Holt, et al.
Advances in Radiation Oncology
|
April 7, 2022
A Prospective Study of a Resorbable Intravesical Fiducial Marker for Bladder Cancer Radiation Therapy
Matthew D Greer, Stephanie K Schaub, Stephen R Bowen, et al.
The Lancet. Oncology
|
February 8, 2022
Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial
Matthew R Smith, Howard I Scher, Shahneen Sandhu, et al.
European Urology
|
July 16, 2019
Incremental Utility of Adjuvant Chemotherapy in Muscle-invasive Bladder Cancer: Quantifying the Relapse Risk Associated with Therapeutic Effect
Filippo Pederzoli, Marco Bandini, Alberto Briganti, et al.
Clinical Genitourinary Cancer
|
September 20, 2017
Venous Thromboembolism Risk in Patients With Locoregional Urothelial Tract Tumors
Jorge D Ramos, Jonathan T Wingate, Roman Gulati, et al.
Bladder Cancer (Amsterdam, Netherlands)
|
June 10, 2021
Plasmacytoid urothelial carcinoma: response to chemotherapy and oncologic outcomes
Leonidas N Diamantopoulos, Ali Raza Khaki, Petros Grivas, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 14, 2021
Phase II Multicenter Study of Enzalutamide in Metastatic Castration-Resistant Prostate Cancer to Identify Mechanisms Driving Resistance
Rana R McKay, Lucia Kwak, Jett P Crowdis, et al.
Page
of 24